Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

The German Network for Personalized Medicine to enhance patient care and translational research

Nature Medicine volume 29, pages 1298–1301 (2023)Cite this article

Subjects

Implementing personalized medicine into a national health care system is a challenging and difficult task. Generally, two different methods have been implemented: a top-down approach based on a national strategy to introduce genomic medicine into different aspects of the healthcare system; or a bottom-up approach, which is often based on regional networks1,2.

ZPMs initially focused on a integrate system of molecular tumor boards (MTBs). From the start, different stakeholders were closely involved in developing the ZPM concept. The involvement of health insurance companies enabled the funding of patient-related services by the public healthcare system, and the implementation of fast-track procedures to decide on the cost coverage of MTB-recommended treatments. At each ZPM, up to 1,000 patients per year receive advanced molecular tumor characterization and interdisciplinary counseling by the MTB, resulting in molecularly guided therapeutic recommendations for about 70% of the patients3.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Fioretos, T. et al. Nat. Med. 28, 1980–1982 (2022).

    Article  CAS  PubMed  Google Scholar 

  2. Taskén, K. et al. Nat. Med. 28, 885–887 (2022).

    Article  PubMed  Google Scholar 

  3. Renovanz, M. et al. Neuroncol. Adv. https://doi.org/10.1093/noajnl/vdad012 (2023).

    Article  Google Scholar 

  4. Joos, S. et al. Mol. Oncol. 13, 535–542 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Horak, P. et al. Cancer Discov. 11, 2780–2795 (2021).

    Article  CAS  PubMed  Google Scholar 

  6. Saiyed, M. M., Ong, P. S. & Chew, L. J. Clin. Pharm. Ther. 42, 251–258 (2017).

    Article  CAS  PubMed  Google Scholar 

  7. Schett, G., McInnes, I. B. & Neurath, M. F. N. Engl. J. Med. 385, 628–639 (2021).

    Article  CAS  PubMed  Google Scholar 

  8. Stenzinger, A. et al. Semin Cancer Biol. 84, 242–254 (2022).

    Article  PubMed  Google Scholar 

  9. Vicente, A. M., Ballensiefen, W. & Jönsson, J. I. J. Transl. Med. 18, 180 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

    A. L. Illert & J. Duyster

  2. Department of Medicine III, Faculty of Medicine, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany

    A. L. Illert

  3. Center for Personalized Medicine (ZPM), Freiburg, Germany

    A. L. Illert, S. Laßmann, M. Werner, M. Boerries, J. Duyster & R. Thimme

  4. Center for Personalized Medicine (ZPM), Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

    A. L. Illert & W. Weichert

  5. Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

    A. Stenzinger, J. Budczies & P. Schirmacher

  6. Center for Personalized Medicine (ZPM), Heidelberg, Germany

    A. Stenzinger, P. Horak, C. P. Schaaf, S. Fröhling, J. Budczies & P. Schirmacher

  7. German Cancer Consortium (DKTK), Heidelberg, Germany

    A. Stenzinger, P. Horak, S. Fröhling, J. Budczies & P. Schirmacher

  8. Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany

    M. Bitzer & N. P. Malek

  9. Center for Personalized Medicine (ZPM), Tübingen, Germany

    M. Bitzer, Y. Möller, J. Beha, Ö. Öner, F. Schmitt, S. Ossowski, O. Kohlbacher & N. P. Malek

  10. Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany

    P. Horak & S. Fröhling

  11. Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany

    V. I. Gaidzik

  12. Center for Personalized Medicine (ZPM), Ulm, Germany

    V. I. Gaidzik & T. Seufferlein

  13. Institute for Surgical Pathology, Medical Center, University of Freiburg, Freiburg, Germany

    S. Laßmann & M. Werner

  14. Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany

    S. Ossowski

  15. Institute for Bioinformatics and Medical Informatics (IBMI), University of Tübingen, Tübingen, Germany

    S. Ossowski & O. Kohlbacher

  16. Institute of Human Genetics, Heidelberg University, Heidelberg, Germany

    C. P. Schaaf

  17. Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany

    M. Hallek

  18. Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany

    T. H. Brümmendorf

  19. Department of Urology, Heinrich-Heine University, Medical Faculty, Düsseldorf, Germany

    P. Albers

  20. Department of Gynecology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

    T. Fehm

  21. Department of Oncology, Hematology, Stem Cell Transplantation, Cell- and Immunotherapies, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany

    P. Brossart

  22. Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT), Dresden, Germany

    H. Glimm

  23. German Cancer Research Center (DKFZ), Heidelberg, Germany

    H. Glimm

  24. Department of Dermatology, University Duisburg-Essen, University Hospital Essen, Essen, Germany

    D. Schadendorf

  25. German Cancer Consortium (DKTK) Partner Site, Essen, Germany

    D. Schadendorf

  26. Department of Medicine A: Hematology, Oncology, and Pneumology, University Hospital Münster (UKM), Münster, Germany

    A. Bleckmann

  27. University Cancer Center (UCT) Frankfurt-Marburg, University Hospital Frankfurt, Goethe University, Frankfurt, Germany

    C. H. Brandts

  28. German Cancer Consortium (DKTK) Partner Site, Frankfurt, Germany

    C. H. Brandts

  29. Institute of Pathology, Heinrich-Heine University and University Hospital, Düsseldorf, Germany

    I. Esposito

  30. Department of Hematology, Oncology and Immunology, University Hospital Marburg and Philipps-University, Marburg, Germany

    E. Mack

  31. Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany

    C. Peters

  32. German Cancer Consortium (DKTK) Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Freiburg, Germany

    C. Peters, M. Werner, M. Boerries & J. Duyster

  33. Department of Oncology, Hematology and BMT with section of Pneumology, University of Hamburg, Hamburg, Germany

    C. Bokemeyer

  34. University Cancer Center, University Medical Center Mainz, Johannes Gutenberg-University, Mainz, Germany

    T. Kindler

  35. Institute for Tumor Metabolism, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany

    H. Algül

  36. Comprehensive Cancer Center Munich TUM, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany

    H. Algül

  37. Comprehensive Cancer Center Munich, Klinikum Großhadern, Ludwig Maximilian University of Munich, Munich, Germany

    V. Heinemann

  38. Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany

    H. Döhner

  39. Comprehensive Cancer Center Mainfranken, Uniklinikum Würzburg, Würzburg, Germany

    R. Bargou

  40. Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Germany

    V. Ellenrieder

  41. Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany

    P. Hillemanns

  42. Comprehensive Cancer Center Central Germany and University Cancer Center Leipzig,, University Medicine Leipzig, Leipzig, Germany

    F. Lordick

  43. Comprehensive Cancer Center Central Germany and Department of Hematology and Internal Oncology, Universitätsklinikum Jena, Jena, Germany

    A. Hochhaus

  44. University Hospital Erlangen, Department of Obstetrics and Gynecology, Friedrich-Alexander-Universität Erlangen, Erlangen, Germany

    M. W. Beckmann

  45. Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nuremberg, Erlangen, Germany

    M. W. Beckmann

  46. Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany

    T. Pukrop

  47. Department of Hematology and Medical Oncology, Augsburg University Hospital, Augsburg, Germany

    M. Trepel

  48. Department of Health Services Management, Ludwig-Maximilians-Universität, Munich, Germany

    L. Sundmacher

  49. Deutsche Krebsgesellschaft (DKG), Berlin, Germany

    S. Wesselmann

  50. Deutsche Krebshilfe, Bonn, Germany

    G. Nettekoven & F. Kohlhuber

  51. Department Medical Information Systems, University Hospital Heidelberg, Heidelberg, Germany

    O. Heinze

  52. Department of Diagnostic and Interventional Radiology, Eberhard Karls University Tübingen, Tübingen, Germany

    K. Nikolaou

  53. Department of Nuclear Medicine, Ulm University Hospital, Ulm, Germany

    A. J. Beer

  54. Department of Neurology and Interdisciplinary Neuro-Oncology, Center for Neuro-Oncology, University Hospital Tübingen, Tübingen, Germany

    G. Tabatabai

  55. Institute of Pathology, Technische Universität München, Munich, Germany

    W. Weichert

  56. German Cancer Consortium (DKTK) Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Munich, Germany

    W. Weichert

  57. Charité Comprehensive Cancer Center, Charité, Berlin, Germany

    U. Keilholz

  58. Institute of Medical Bioinformatics and Systems Medicine (IBSM), Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

    M. Boerries

  59. Comprehensive Cancer Center Freiburg (CCCF), Freiburg, Germany

    C. Peters, M. Werner, M. Boerries, J. Duyster & R. Thimme

  60. Institute for Translational Bioinformatics, University Medical Center, Tübingen, Germany

    O. Kohlbacher

  61. Department of Computer Science, Applied Bioinformatics, University of Tübingen, Tübingen, Germany

    O. Kohlbacher

  62. Department of Medicine II, Freiburg, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

    R. Thimme

  63. Department of Internal Medicine I, University Hospital, University of Ulm, Ulm, Germany

    T. Seufferlein

  64. M3 Research Institute University Hospital Tübingen, Tübingen, Germany

    Y. Möller & N. P. Malek

  65. Bavarian Cancer Research Center (BZKF), Partner Site TU Munich, Munich, Germany

    A. L. Illert & W. Weichert

  66. Center for integrated Oncology (CIO-ABCD), Aachen-Bonn-Cologne-Düsseldorf, Germany

    M. Hallek, T. H. Brümmendorf, P. Albers, T. Fehm & P. Brossart

  67. Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

    H. Glimm

  68. Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany

    H. Glimm

  69. German Cancer Consortium (DKTK), Dresden, Germany

    H. Glimm

  70. National Center for Tumor Diseases (NCT), NCT-West, Campus Essen, Essen, Germany

    D. Schadendorf

  71. Westdeutsches Tumorzentrum (WTZ), Essen, Germany

    D. Schadendorf

  72. Research Alliance Ruhr – Research Center One Health, University Duisburg-Essen, Essen, Germany

    D. Schadendorf

  73. West German Cancer Center, University Hospital Münster, Münster, Germany

    A. Bleckmann

  74. Center for Personalized Medicine (ZPM), Düsseldorf, Germany

    I. Esposito

  75. German Cancer Consortium (DKTK) Partner Site Mainz, Mainz, Germany

    T. Kindler

  76. Department of Medicine III, Klinikum Großhadern, Ludwig Maximilian University of Munich, Munich, Germany

    V. Heinemann

  77. Bavarian Cancer Research Center (BZKF), Partner Site Würzburg, Würzburg, Germany

    R. Bargou

  78. Bavarian Cancer Research Center (BZKF), Partner Site Erlangen, Erlangen, Germany

    M. W. Beckmann

  79. Comprehensive Cancer Center Ostbayern, Regensburg, Germany

    T. Pukrop

  80. Bavarian Cancer Research Center (BZKF), Partner Site Regensburg, Regensburg, Germany

    T. Pukrop

  81. Comprehensive Cancer Center Augsburg, CCC Alliance WERA, Augsburg, Germany

    M. Trepel

  82. Bavarian Cancer Research Center (BZKF), Partner Site Augsburg, Augsburg, Germany

    M. Trepel

  83. Comprehensive Cancer Center Tübingen-Stuttgart, Stuttgart, Germany

    G. Tabatabai

Authors
  1. A. L. Illert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Stenzinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Bitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Horak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. I. Gaidzik
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Beha
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ö. Öner
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Laßmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S. Ossowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C. P. Schaaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. Hallek
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. T. H. Brümmendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. P. Albers
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. T. Fehm
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. P. Brossart
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. H. Glimm
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. D. Schadendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. A. Bleckmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. C. H. Brandts
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. I. Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. E. Mack
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. C. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. C. Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. S. Fröhling
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. T. Kindler
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. H. Algül
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. V. Heinemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. H. Döhner
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. R. Bargou
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. V. Ellenrieder
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. P. Hillemanns
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. F. Lordick
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. A. Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. M. W. Beckmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  37. T. Pukrop
    View author publications

    You can also search for this author in PubMed Google Scholar

  38. M. Trepel
    View author publications

    You can also search for this author in PubMed Google Scholar

  39. L. Sundmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  40. S. Wesselmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  41. G. Nettekoven
    View author publications

    You can also search for this author in PubMed Google Scholar

  42. F. Kohlhuber
    View author publications

    You can also search for this author in PubMed Google Scholar

  43. O. Heinze
    View author publications

    You can also search for this author in PubMed Google Scholar

  44. J. Budczies
    View author publications

    You can also search for this author in PubMed Google Scholar

  45. M. Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  46. K. Nikolaou
    View author publications

    You can also search for this author in PubMed Google Scholar

  47. A. J. Beer
    View author publications

    You can also search for this author in PubMed Google Scholar

  48. G. Tabatabai
    View author publications

    You can also search for this author in PubMed Google Scholar

  49. W. Weichert
    View author publications

    You can also search for this author in PubMed Google Scholar

  50. U. Keilholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  51. M. Boerries
    View author publications

    You can also search for this author in PubMed Google Scholar

  52. O. Kohlbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  53. J. Duyster
    View author publications

    You can also search for this author in PubMed Google Scholar

  54. R. Thimme
    View author publications

    You can also search for this author in PubMed Google Scholar

  55. T. Seufferlein
    View author publications

    You can also search for this author in PubMed Google Scholar

  56. P. Schirmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  57. N. P. Malek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. P. Malek.

Ethics declarations

Competing interests

A.L.I. received honoraria for consulting and advisory boards from Janssen-Cilag, AbbVie, Roche, AstraZeneca, Amgen and Takeda. A.S. has received honoraria for consulting and/or advisory boards from Agilent, Aignostics, Amgen, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, Roche, Seagen, Takeda, and Thermo Fisher; and grants from Bayer, BMS, Chugai, and Incyte. M.B. received honoraria for advisory boards from Roche, Incyte Biosciences Germany, Bayer Vital, BMS, MSD Sharp & Dome, Taiho Oncology Europe, and EISAI. V.I.G. is on the advisory board for Jazz Pharmaceuticals and Abbvie; received speakers bureau fees for Pfizer, Janssen, and Abbvie; and travel support from Abbvie. S.L. reports research grant from BMS, advisory board/speaker invitation from AstraZeneca, Eli Lily, Roche, and Takeda outside of this work. S.O. received honoraria for workshop presentations at conferences from Illumina. M.H. received honoraria for lectures, presentations, speakers bureaus and consulting advisory boards from Abbvie, Roche, AstraZeneca, Gilead, Janssen, and Beigene. P.A. received fees from Ferring Pharmaceuticals and Bayer. T.F. received honoraria from Onkowissen. P.B. received honoraria for consulting and advisory boards from Bristol Myers Squibb, AstraZeneca, Amgen, and MSD. D.S. has been on the advisory board, an invited speaker, or committee member for BMS, Immunocore, Merck Serono, MSD, Neracare, Novartis, Pfizer, Philogen, Pierre Fabre, Roche, Sanofi, and Regeneron; received research grants from or been principal investigator for BMS, MSD, Novartis, Philogen, Pierre Fabre, and Sanofi; and is a member of the board of directors for EORTC-MG. A.B. received honoraria for consulting and advisory boards from MSD, Boehringer Ingelheim, Takeda, AstraZeneca, BMS, Lilly, Roche Pharma, Pfizer, Sanofi, Janssen-Cilag, Bayer Vital, Amgen, Novartis, and Daiichi Sankyo. C.H.B. received honoraria for consulting and advisory boards from MSD, BMS and Novartis. I.E. received consulting fees from Incyte Bioscience International. E.M. received speaker honoraria from Roche and Boehringer Ingelheim; and is on an advisory board for Roche. C.B. has been on the advisory board, an invited speaker, or committee member for AOK Germany, AstraZeneca, Bayer Healthcare, BioNTech, Bristol Myers Squipp, Jansen Cilag, Med Update, Merck Serono, Oncology Drug Consult CRO, Roche Pharma, and Sanofi Aventis; several clinical trials sponsored by industry; member of board of directors for DGHO and Northern German Society of Internal Medicine; leadership roles at Hamburg Cancer Society and National Network of German Cancer Centers (DKH); and advisory role at board of DGHO advisors. S.F. received consulting fees or advisory board membership from Bayer, Illumina, and Roche; honoraria from Amgen, Eli Lilly, PharmaMar, and Roche; research funding from AstraZeneca, Pfizer, PharmaMar, and Roche; and travel or accommodation expenses from Amgen, Eli Lilly, Illumina, PharmaMar, and Roche. H.A. received honoraria for consulting and advisory boards from AstraZeneca, Viatris, Pfizer, and Servier. V.H. declares honoraria for talks and advisory board roles from Merck, Amgen, Roche, Sanofi, SIRTEX, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS, MSD, Novartis, Boehringer Ingelheim, Celgene, Terumo, Oncosil, Seagen, and NORDIC Pharma; and research funding from Merck, Amgen, Roche, Sanofi, Pfizer, Boehringer Ingelheim, SIRTEX, and Servier. R.B. is patent holder for blinatumomab, from which he receives royalty payments, and has consulted for and received honoraria from Amgen, Cellex, and Gemoab. P.H. received honoraria from MSD and AstraZeneca. F.L. received honoraria from Astellas, AstraZeneca, BMS, MSD, and Roche. A.H. received research support from Novartis, BMS, Pfizer, and Incyte. M.T. received honoraria for consulting or advisory boards from Janssen-Cilag, Roche, AstraZeneca, Amgen, Takeda, BMS, IO Medico, Sana, RKH Kliniken, ConEvent, Med Update, VHS Stadtbergen, I-Med Institut, and Klinikum Esslingen. J.B. received honoraria from MSD. M.W. reports research grant from BMS outside of this work. A.J.B. received honoraria for talks, consulting, or advisory boards from Siemens Healthineers, NVision, and AAA/Novartis. G.T. has served on advisory boards for Bayer, Boehringer Ingelheim, CureVac, and Novocure, consulted for Bayer, Boehringer Ingelheim, and CureVac; was a steering committee member in non-interventional trials for Bayer and Novocure; with financial compensation for all these activities provided as institutional funding to the University Hospital Tübingen. W.W. received research grants from Roche, MSD, BMS, and AstraZeneca; advisory board, lectures, speaker bureaus fees from Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Janssen, Amgen, Astellas, Illumina, Eisai, Siemens, Agilent, ADC, GSK, and Molecular Health. U.K. received research support from AstraZeneca; and honoraria from BMS, MSD, Merck, and Novartis. T.S. received honoraria for consulting of editorial boards for Servier, M&D, BMS, Mirati, Olympus Fondation Pierre Fabre, and Eli Lilly. P.S. received honoraria from speakers bureau or advisory boards for Incyte, BMS, Eisai, MSD, AstraZeneca, and Amgen; and from BMS, Gilead, Incyte, and Huygai. All other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Illert, A.L., Stenzinger, A., Bitzer, M. et al. The German Network for Personalized Medicine to enhance patient care and translational research. Nat Med 29, 1298–1301 (2023). https://doi.org/10.1038/s41591-023-02354-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02354-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing